Learn how organizations can balance access, affordability, and outcomes through thoughtful benefits design
GLP-1 medications have quickly become one of the most significant developments in employer-sponsored health plans.1 Originally developed to treat type 2 diabetes, these therapies have gained widespread attention for their effectiveness in treating obesity and supporting weight management.
As demand grows, employers are navigating a complex challenge. Employees are seeking access to these therapies, while employers face rising pharmacy costs, evolving clinical guidance, and pressure to maintain sustainable benefits programs.1
The question is no longer simply whether GLP-1s should be covered. It’s how access can be delivered in a way that is affordable, understandable, and sustainable.
Few therapies have reshaped benefits conversations as quickly as GLP-1s.
Employers are reporting growing interest in GLP-1 medications among covered members while continuing to manage the significant cost implications associated with these therapies.2 As a result, employers are playing a larger role in determining how coverage is structured and how employees access these therapies through their health benefits.1
This creates a delicate balancing act. Restrict access too heavily, and organizations risk employee dissatisfaction and missed opportunities to improve health outcomes. Provide unrestricted access, and costs can quickly become difficult to manage.
Many employers are finding that access and affordability should be addressed together.
Employers are taking a multifaceted approach to GLP-1 access. Many organizations are implementing structured coverage policies, including clinical criteria and other utilization management strategies, to balance access with long-term affordability.3 At the same time, many employers are complementing coverage with weight management programs, lifestyle coaching, and other support resources designed to promote long-term health outcomes.4
These approaches are intended to improve access while supporting responsible plan management and long-term treatment success.
Even when coverage is available, employees may still face barriers to treatment. Deductibles, coinsurance, documentation requirements, and reimbursement questions can all affect whether care feels accessible.
Employees want to understand:
For employers, improving access means considering the entire benefits experience, not just the coverage decision itself.
As employers look for sustainable ways to support employees, consumer-directed healthcare accounts can be a key factor in improving affordability.
Health savings accounts (HSAs), flexible spending accounts (FSAs), and health reimbursement arrangements (HRAs) provide employees with additional resources to manage eligible healthcare expenses and navigate rising treatment costs. These account-based benefits can help reduce financial barriers while giving employers greater flexibility as GLP-1 strategies continue to evolve.
Rather than relying on a single solution, many organizations are combining health plan design, consumer-directed benefits, and employee education to create a more supportive healthcare experience.
The GLP-1 conversation will continue to evolve as new therapies enter the market and employer strategies mature. What is already clear is that employers have an important role to play in shaping access.
Organizations that focus on balancing access, affordability, and outcomes will be better positioned to support employees while maintaining a sustainable approach to benefits management. By combining thoughtful plan design, clear communication, and flexible consumer-directed healthcare solutions, employers can help employees navigate treatment options with greater confidence.
As employers evaluate plan design, consumer-directed healthcare benefits can play an important role in reducing financial barriers and improving the employee experience. Alegeus enables benefits administrators and health plans to deliver consumer-directed healthcare account solutions through a flexible technology platform that evolves with changing healthcare needs. Contact us to learn more.
1 Willis Towers Watson (WTW). GLP-1 Drugs in 2025: Cost, Access and the Future of Obesity Treatment.
2 Business Group on Health. 2026 Employer Health Care Strategy Survey.
3 Employee Benefit Research Institute (EBRI). GLP-1 Coverage and Its Impact on Employment-Based Health Plan Premiums: A Simulation-Based Analysis and WTW.
4 Peterson Health Technology Institute (PHTI). Employer Approaches to GLP-1 Coverage.